Dr Reddy's, Aurigene and DNDi link up on affordable drugs for neglected tropical diseases

2 September 2022

Indian generic drugs major Dr Reddy’s Laboratories (BSE: 500124) and Aurigene Pharmaceutical Services Limited (APSL), a contract research, development and manufacturing services organization and fully owned stepdown subsidiary of Dr Reddy's, announced a Memorandum of Understanding (MoU) with the Drugs for Neglected Diseases initiative (DNDi), a not-for-profit research and development body that develops new therapeutic solutions for neglected diseases and the DNDi India Foundation.

The parties will explore a potential collaboration to develop and market novel and improved drugs for the treatment of identified neglected tropical diseases (NTDs) of national and global importance. They will also seek to work towards ensuring access of those drugs at affordable prices to patients in need particularly in low and middle-income countries (LMICs) that are disproportionately affected by these NTDs.

Bringing together expertise

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK